within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BA16_ImidazoleSalicylate;

model ImidazoleSalicylate
  extends Pharmacolibrary.Drugs.ATC.N.N02BA16;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N02BA16</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Imidazole salicylate is a nonsteroidal anti-inflammatory drug (NSAID) that combines the anti-inflammatory properties of salicylates with the antifungal/antibacterial properties of imidazoles. It has been used primarily as an analgesic and antipyretic, but is not widely approved or commonly used today.</p><h4>Pharmacokinetics</h4><p>No dedicated publications reporting pharmacokinetic parameters for imidazole salicylate in humans could be identified. The following are estimated parameters based on the typical profile of acetylsalicylic acid (aspirin) and properties of salicylate esters.</p><h4>References</h4><ol><li><p>Kuemmerle, HP, et al., &amp; Hitzenberger, G (1986). Pharmacokinetic profile of imidazole 2-hydroxybenzoate, a novel nonsteroidal antiinflammatory agent. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 24(11) 581â€“597. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3793293/&quot;>https://pubmed.ncbi.nlm.nih.gov/3793293</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end ImidazoleSalicylate;
